Trial Profile
Phase II clinical trial of pazopanib with unresectable or metastatic malignant peripheral nerve sheath tumor (1st cohort) and in patients with chemoresistant tumors; alveolar soft part sarcoma, epithelioid sarcoma, and clear cell sarcoma (2nd cohort)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2022
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Alveolar soft part sarcoma; Clear cell sarcoma; Nerve sheath neoplasms; Sarcoma
- Focus Therapeutic Use
- 14 Apr 2022 Planned End Date changed from 31 Aug 2019 to 14 Jan 2023.
- 01 Sep 2020 Results assessing effect of pazopanib on chemoresistant sarcomas (ASPS, ES, and CCS) from Cohort 2 of this study published in the Cancer Science
- 31 May 2020 Status changed from active, no longer recruiting to completed according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.